| Products/Services Used | Details | Operation |
|---|---|---|
| Recombinant Proteins | P1 and CRF came from GenScript (Piscataway, NJ), T and AT were from Haematolgic Technology (Essex Junction, VT), P2 was obtained from Biomatik (Wilmington, DE), TNF came from ProSpec (East Brunswick, NJ), and Hep (estimated 16.5 kDa average) was from Alfa Aesar (Haverhill, MA). | Get A Quote |
Preterm birth (PTB) related health problems take over one million lives each year, and currently, no clinical analysis is available to determine if a fetus is at risk for PTB. Here, we describe the preparation of a key PTB risk biomarker, thrombin-antithrombin (TAT), and characterize it using dot blots, MS, and microchip electrophoresis (µCE). The pH for fluorescently labeling TAT was also optimized using spectrofluorometry and spectrophotometry. The LOD of TAT was measured in µCE. Lastly, TAT was combined with six other PTB risk biomarkers and separated in µCE. The ability to make and characterize TAT is an important step toward the development of an integrated microfluidic diagnostic for PTB risk.,© 2019 ... More
